Promore Pharma AB

Promore Pharma AB

Promore Pharma AB

Overview
Date Founded

2003

Headquarters

Fogdevreten 2,Solna, Stockholm 171 65

Type of Company

Public

Employees (Worldwide)

1

Industries

Biotechnology

Company Description

Promore Pharma AB is a biopharmaceutical company, which engages in the development of therapeutic peptides for the bioactive wound care market. Its projects include PXL01 and LL-37. The PXL01 project will be used for prevention of post-surgical adhesions and scars is being prepared for clinical Phase III-studies in patients undergoing tendon repair surgery in the hand. The LL-37 project will used to prepare for a clinical Phase IIb study in patients with venous leg ulcers. The company was founded by Mona Ståhle and Johan Heilborn on January 29, 2003 and is headquartered in Solna, Sweden.

Website

http://www.promorepharma.com

Contact Data
Trying to get in touch with decision makers at Promore Pharma AB? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
In The News
ENP Newswire
November 25, 2020
-Promore Pharma AB - Interim report January, September 2020
ENP Newswire
November 23, 2020
-Invitation to Conference Call regarding Promore Pharma's Interim Report for the Third Quarter 2020
ENP Newswire
November 23, 2020
-Promore Pharma - Clarification of outcome in the clinical trial HEAL LL-37
ENP Newswire
November 20, 2020
-Promore Pharma announces positive results from Phase IIb study of ropocamptide in the treatment of venous leg ulcers
ENP Newswire
October 28, 2020
-Nomination Committee Appointed for the Annual General Meeting 2021 in Promore Pharma

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.
Executives & Employees
See More
Jonas Göran Ekblom

President & Chief Executive Officer

Erik Magnusson

Chief Financial Officer

Ulrika Maria Wennberg

Chief Operating Officer

Margit Mahlapuu

Chief Scientific Officer

Christel Biebuyck

Office Manager

Melonie Johansson

Assistant Office Manager

Board of Directors
Nils-Göran Pettersson

Vice Chairman at Mobidiag Oy

Marianne Dicander Alexandersson

Chairman at MDA Management AB

Kerstin Valinder Strinnholm

Industrial Advisor at Segulah Advisor AB

Torsten Rüdiger Goesch

Partner at Rosetta Capital Ltd.

Göran Harald Linder

Managing Director at Midroc New Technology AB

Satyendra Kumar

Former Vice President-Research & Development at Pharma Research Products Co., Ltd.

Trending People
Christian Democratic Union of Germany
Germany: Merkel's party elects pragmatic Laschet as leader - St. Paul Pioneer Press (Minnesota)
Boston Scientific Corporation
Solving the Split Incentive Dilemma in Energy Retrofits - Commercial Property Executive
The Federal Bureau of Prisons
Federal prisons on lockdown in run-up to Biden inauguration - The Independent UK
3M Innovative Properties Co.
3M Innovative Properties Assigned Patent for Methods of Making Metal Bond Abrasi... - Targeted News Service
Boston Scientific Scimed, Inc.
Boston Scientific Scimed Assigned Patent for Attachment Clamp - Targeted News Service
Trending Organizations
Christian Democratic Union of Germany
Germany: Merkel's party elects pragmatic Laschet as leader - St. Paul Pioneer Press (Minnesota)
Boston Scientific Corporation
Solving the Split Incentive Dilemma in Energy Retrofits - Commercial Property Executive
The Federal Bureau of Prisons
Federal prisons on lockdown in run-up to Biden inauguration - The Independent UK
3M Innovative Properties Co.
3M Innovative Properties Assigned Patent for Methods of Making Metal Bond Abrasi... - Targeted News Service
Boston Scientific Scimed, Inc.
Boston Scientific Scimed Assigned Patent for Attachment Clamp - Targeted News Service
Paths to Promore Pharma AB
Potential Connections via
Relationship Science
You
Promore Pharma AB
Recent Transactions
Details Hidden

Pharma Research Products Co., Ltd. purchases Promore Pharma AB from Pergamum AB

Details Hidden

Promore Pharma AB issued SEK Units Consisting of Common Stock and Warrants

Details Hidden

Midroc New Technology AB, Pergamum AB, Karolinska Development AB purchase Promore Pharma AB

Transaction Advisors
Auditor
Deloitte AB

Advised onPromore Pharma AB issued SEK Units Consisting of Common Stock and Warrants

Investment Advisor
Redeye AB

Advised onPromore Pharma AB issued SEK Units Consisting of Common Stock and Warrants
Advisors & Consultants
Advisor
Jenni Björnulfson

Chief Financial Officer at Cinclus Pharma Holding AB
Key Stats and Financials As of 2019
Market Capitalization
$11.3M
Total Enterprise Value
$8.37M
Earnings Per Share
$-0.09
EBITDAMargin
-707.15%
Enterprise Value / Sales
18.9x
TEVNet Income
-2.57x
Debt TEV
0.01x
Three Year Compounded Annual Growth Rate Of Revenue
307.6%
Revenue
$443K
Net Profit
$-3.26M
EBITDA
$-3.13M
Total Debt
$80.5K
Total Equity
$5.89M
Investors
Details Hidden
Johan Heilborn

Co-Founder at Promore Pharma AB

Details Hidden
Mona Ståhle

Senior Physician & Professor, Department of Medicine at Karolinska Institutet

Details Hidden
Karolinska Development AB (Private Equity)

KD's investment approach aims to transfer life sciences innovations into commercial applications while improving human health. They are an early investor with the objective of being the lead investor. They generally maintain a significant position in their portfolio firms until exit. They endeavor to rapidly build value in high risk opportunities.Among key investment criteria, they seek innovations, either pharmaceutical or medical technology applications, which address unmet medical needs. KD looks for opportunities displaying a strong IP position, preferably with a patent application, as well as unique skills or processes.KD works closely with regional Nordic academic and research institutions. Their deal flow agreement with Karolinska Institutet Innovations ensures priority access of promising opportunities at a very early stage. In addition to capital infusion, the firm supports their investments through business development expertise, technical specialists and access to their wide-ranging professional network.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Promore Pharma AB. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Promore Pharma AB's profile does not indicate a business or promotional relationship of any kind between RelSci and Promore Pharma AB.